$ARTH
Arch Therapeutics, Inc.

2023 Q2 Form 10-Q Financial Statement

#000143774923015498 Filed on May 23, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $13.29K $16.65K
YoY Change 112.31% 432.08%
Cost Of Revenue $18.53K $18.72K
YoY Change 8.1% 7.39%
Gross Profit -$5.236K -$2.064K
YoY Change -51.87% -85.57%
Gross Profit Margin -39.39% -12.39%
Selling, General & Admin $870.1K $1.253M
YoY Change 4.05% 3.63%
% of Gross Profit
Research & Development $139.0K $170.6K
YoY Change -13.01% -67.66%
% of Gross Profit
Depreciation & Amortization $273.00 $380.00
YoY Change -65.83% -52.44%
% of Gross Profit
Operating Expenses $1.009M $1.423M
YoY Change 1.31% -18.03%
Operating Profit -$1.014M -$1.425M
YoY Change 0.73% -18.58%
Interest Expense $808.8K $635.2K
YoY Change 1927.5% 1510.03%
% of Operating Profit
Other Income/Expense, Net -$808.8K $523.0K
YoY Change 1927.5% -45.55%
Pretax Income -$1.823M -$902.5K
YoY Change 74.16% 14.19%
Income Tax
% Of Pretax Income
Net Earnings -$1.823M -$902.5K
YoY Change 74.16% 14.19%
Net Earnings / Revenue -13714.79% -5418.98%
Basic Earnings Per Share -$1.42 -$0.71
Diluted Earnings Per Share -$1.42 -$0.71
COMMON SHARES
Basic Shares Outstanding 1.285M 1.263M
Diluted Shares Outstanding 1.280M shares

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $86.54K $29.50K
YoY Change 57.35% -45.78%
Cash & Equivalents $86.54K $29.50K
Short-Term Investments
Other Short-Term Assets $90.54K $156.4K
YoY Change 8.44% -13.26%
Inventory $1.383M $1.402M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.560M $1.588M
YoY Change -0.43% 10.89%
LONG-TERM ASSETS
Property, Plant & Equipment $728.00 $1.001K
YoY Change -74.39% -72.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.500K $3.500K
YoY Change 0.0% 0.0%
Total Long-Term Assets $4.228K $4.501K
YoY Change -33.34% -36.98%
TOTAL ASSETS
Total Short-Term Assets $1.560M $1.588M
Total Long-Term Assets $4.228K $4.501K
Total Assets $1.564M $1.593M
YoY Change -0.56% 10.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.471M $2.426M
YoY Change 45.69% 88.33%
Accrued Expenses $1.021M $851.5K
YoY Change 357.68% 444.68%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $5.347M $4.436M
YoY Change
Total Short-Term Liabilities $9.579M $7.979M
YoY Change 399.1% 452.39%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.579M $7.979M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $9.579M $7.979M
YoY Change 71.41% 77.35%
SHAREHOLDERS EQUITY
Retained Earnings -$59.60M -$57.78M
YoY Change 12.06% 10.81%
Common Stock $51.58M $51.39M
YoY Change 21665.6% 21590.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$8.015M -$6.386M
YoY Change
Total Liabilities & Shareholders Equity $1.564M $1.593M
YoY Change -0.56% 10.65%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$1.823M -$902.5K
YoY Change 74.16% 14.19%
Depreciation, Depletion And Amortization $273.00 $380.00
YoY Change -65.83% -52.44%
Cash From Operating Activities -$897.5K -$599.9K
YoY Change 56.26% -41.97%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 954.6K 618.8K
YoY Change 66.02%
NET CHANGE
Cash From Operating Activities -897.5K -599.9K
Cash From Investing Activities
Cash From Financing Activities 954.6K 618.8K
Net Change In Cash 57.04K 18.89K
YoY Change 9567.8% -101.83%
FREE CASH FLOW
Cash From Operating Activities -$897.5K -$599.9K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 usd
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
0 usd
CY2023Q1 us-gaap Liabilities
Liabilities
7978817 usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
dei Entity Central Index Key
EntityCentralIndexKey
0001537561
CY2022Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
318505 usd
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
645712 usd
CY2022Q3 us-gaap Interest Payable Current
InterestPayableCurrent
127781 usd
CY2023Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 usd
CY2022Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
748275 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7978817 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3320494 usd
CY2023Q1 arch Interest Payable Noncurrent
InterestPayableNoncurrent
0 usd
CY2022Q3 arch Interest Payable Noncurrent
InterestPayableNoncurrent
204575 usd
CY2022Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
459200 usd
CY2022Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3476048 usd
CY2022Q3 us-gaap Liabilities
Liabilities
6796542 usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
68524 usd
CY2023Q1 arch Stock And Warrants Issued During Period Value New Issues Net Of Financing Costs
StockAndWarrantsIssuedDuringPeriodValueNewIssuesNetOfFinancingCosts
287420 usd
CY2023Q1 arch Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
49278 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-6386088 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-4192803 usd
us-gaap Net Income Loss
NetIncomeLoss
-2702533 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
172550 usd
arch Stock And Warrants Issued During Period Value New Issues Net Of Financing Costs
StockAndWarrantsIssuedDuringPeriodValueNewIssuesNetOfFinancingCosts
287420 usd
arch Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
49278 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-6386088 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-2423678 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-790318 usd
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
154572 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-3059424 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-1025674 usd
us-gaap Net Income Loss
NetIncomeLoss
-2340465 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
306715 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-0 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
1000000 usd
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
1158197 usd
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
-0 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
846147 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
0 usd
us-gaap Inventory Write Down
InventoryWriteDown
0 usd
us-gaap Inventory Write Down
InventoryWriteDown
248073 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-12464 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
351876 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-280058 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-127080 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1097894 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
879995 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
313356 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
79781 usd
arch Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
-112713 usd
arch Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
-163135 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1249931 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2212234 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
212514 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
-0 usd
arch Proceeds From Shareholder Advances
ProceedsFromShareholderAdvances
230000 usd
arch Proceeds From Shareholder Advances
ProceedsFromShareholderAdvances
0 usd
arch Proceeds From Issuance Of Common Stock And Warrants Net Of Financing Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfFinancingCosts
515000 usd
arch Proceeds From Issuance Of Common Stock And Warrants Net Of Financing Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfFinancingCosts
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
532486 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-717445 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2212234 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2266639 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29495 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
54405 usd
arch Warrants Exchanged For Common Stock Noncash
WarrantsExchangedForCommonStockNoncash
49278 usd
arch Warrants Exchanged For Common Stock Noncash
WarrantsExchangedForCommonStockNoncash
0 usd
arch Issuance Of Restricted Stock
IssuanceOfRestrictedStock
3019 usd
arch Issuance Of Restricted Stock
IssuanceOfRestrictedStock
19887 usd
us-gaap Stock Issued1
StockIssued1
25840 usd
us-gaap Stock Issued1
StockIssued1
0 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Use Of Estimates
UseOfEstimates
<span style="text-decoration: underline; ">Use of Estimates</span>Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ from those estimates.
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<span style="text-decoration: underline; ">Concentration of Credit Risk</span>Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash.
CY2023Q1 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
1158197 usd
CY2023Q1 arch Reclassification Of Exchanged Notes Included In Notes Payable To Unsecured Convertible Notes
ReclassificationOfExchangedNotesIncludedInNotesPayableToUnsecuredConvertibleNotes
699781 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
33756 usd
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
33756 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
32755 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
31712 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1001 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2044 usd
CY2023Q1 us-gaap Depreciation
Depreciation
380 usd
CY2022Q1 us-gaap Depreciation
Depreciation
799 usd
us-gaap Depreciation
Depreciation
1043 usd
us-gaap Depreciation
Depreciation
1598 usd
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
625
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
76274 usd
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
9063 usd
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
1326110 usd
CY2022Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1405785 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
1402384 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
1414848 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
98626
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
52.00
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P1Y4M9D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
16900 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
24500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
18801
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
70.00
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
104325
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
39.00
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y11M12D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
104300 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
74000
arch Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
50.00
arch Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
P4Y10M20D
arch Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue
74000 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
104325
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
39.00
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y11M12D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
104300 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
18.00
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
20.00
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
18.00
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
20.00
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
20.00
CY2016Q3 arch Shelf Registration Statement Maximum Amount Authorized
ShelfRegistrationStatementMaximumAmountAuthorized
50000000 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
1158197 usd
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
215625
CY2022Q3 arch Percentage Of Principal Amount
PercentageOfPrincipalAmount
0.15 pure
CY2022Q3 arch Proceeds From Issuance Of Convertible Notes Common Stock And Warrants Gross
ProceedsFromIssuanceOfConvertibleNotesCommonStockAndWarrantsGross
3500000 usd
CY2022Q3 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
775000 usd
CY2022Q3 arch Placement Agents Fees
PlacementAgentsFees
555000 usd
CY2023Q1 arch Proceeds From Issuance Of Convertible Notes Common Stock And Warrants Gross
ProceedsFromIssuanceOfConvertibleNotesCommonStockAndWarrantsGross
530000 usd
arch Placement Agents Fees
PlacementAgentsFees
15000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25840 usd
arch Proceeds From Shareholder Advances
ProceedsFromShareholderAdvances
230000 usd
arch Proceeds From Shareholder Advances
ProceedsFromShareholderAdvances
538000 usd

Files In Submission

Name View Source Status
0001437749-23-015498-index-headers.html Edgar Link pending
0001437749-23-015498-index.html Edgar Link pending
0001437749-23-015498.txt Edgar Link pending
0001437749-23-015498-xbrl.zip Edgar Link pending
arch-20230331.xsd Edgar Link pending
arch20230331_10q.htm Edgar Link pending
ex_499766.htm Edgar Link pending
ex_499767.htm Edgar Link pending
ex_499768.htm Edgar Link pending
ex_521144.htm Edgar Link pending
ex_521145.htm Edgar Link pending
ex_523712.htm Edgar Link pending
ex_523713.htm Edgar Link pending
ex_523714.htm Edgar Link pending
ex_523715.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
arch-20230331_def.xml Edgar Link unprocessable
arch-20230331_lab.xml Edgar Link unprocessable
arch-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
arch20230331_10q_htm.xml Edgar Link completed
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
arch-20230331_cal.xml Edgar Link unprocessable